Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

Exclusion Criteria

• •1. Patients with any ongoing clinically significant adverse events at the end of the study ROP111528.
• •2. Subjects with severe, clinically significant condition(s) other than Parkinson's disease which, in the opinion of the investigator, would render the subject unsuitable for the study (e.g., psychiatric, hematological, renal, hepatic, endocrinology, neurological (other than Parkinson's disease), cardiovascular, or active malignancy (other than basal cell carcinoma).
• •3. Subjects with clinically significant abnormalities in Laboratory or ECG tests at the end of the study ROP111528.
• •4. Subjects with severe dizziness or fainting due to postural hypotension on standing.
• •5. Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacine, fluvoxamine, cimetidine, ethinyloestradiol) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrolment. Subjects already on chronic therapy with any of these agents may be enrolled but doses must have remained stable from 7 days prior to enrolment through the end of the treatment period.
• •6. Women who are pregnant or breast-feeding.
• •7. Use of an investigational drug throughout the treatment period.